UAE says Sinopharm vaccine has 86% efficacy against COVID-19
DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there.
The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups.
The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.
“The analysis shows no serious safety concerns,” it said.
It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.
Based on XDL past trends January seems to be the month where its price rise up. Go invest something else first while waiting for this Black Thorn to bear fruit.
United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19
TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.
The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.
The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.
The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”
The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.
Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.
“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.
“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.
SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.
Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.
“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.
Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.
The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.
Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.
Govt to increase Covid-19 vaccine purchase to cover 60%-70% of M'sians — PM
The government has plans to increase its purchase of the Covid-19 vaccine to cover the immunisation needs of about 60%-70% of Malaysians compared with 30% currently.
Prime Minister Tan Sri Muhyiddin Yassin said this was because some nations had purchased doses exceeding their population.
“As for Malaysia, we have already got 30%. I have instructed Health Minister Datuk Seri Dr Adham Baba along with [Science, Technology and Innovation Minister] Khairy Jamaluddin Abu Bakar to negotiate and increase it from 30% to 60% or 70%.
This is my second time on XDL this year.The trend still up.This counter not cheating but buying a company with market cap 150 million with over 500 million in cash with less borrowing.My buying based on pattern and is up.
Seems like xdl reusable mask malaysian sole distributor counter at long resistance duels. Waiting Seacera announcement on masks market share prospect and guidance for 2021.
Caution!! Stop using your precious "CASH" to buy this "Toilet Tissue Share". It's is unworthy and useless share. With all the PPE and Face Mask business coupled with approved Buy-Back, yet so many sellers queque to sell practically everyday. Who hold the most company shares and willing to depart hurriedly for the "CASH" and had no confidence on this Conmen China company? The more we buy, the more the price will dropped further. Lastly, smart investor, don't buy!!!
I)Less Posting Ii)The trend now on China company shares since Nov 2020. III)Short term trend 3 days in a row showing 7.5 cents buying. IV)China company are secretive on their plan until it's really real then announce. V) This company cash in Rm over 500 million.
Posted by rictan10 > Dec 28, 2020 10:52 AM | Report Abuse
Caution!! Stop using your precious "CASH" to buy this "Toilet Tissue Share". It's is unworthy and useless share. With all the PPE and Face Mask business coupled with approved Buy-Back, yet so many sellers queque to sell practically everyday. Who hold the most company shares and willing to depart hurriedly for the "CASH" and had no confidence on this Conmen China company? The more we buy, the more the price will dropped further. Lastly, smart investor, don't buy!!!
solid bottom formations have been done, amazing rock bottom, you guys can start buying in at 0.07-0.075 from today onwards..nothing much to lose.. it hardly goes back to 0.055 or 0.05.. it spent so much time to build the foundation. the ONLY PURPOSE to jack up the price within the coming few months.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
David Coperfield
1,118 posts
Posted by David Coperfield > 2020-12-08 00:44 | Report Abuse
https://koonyewyin.com/2020/12/07/additional-gloves-are-required-to-inject-vaccines/